News

A panel convened by leading organizations formulated recommendations for role, timing, and sequencing of blood and bone marrow transplantation and CAR-T therapy for newly diagnosed and relapsed/refractory MCL.

Study findings show the addition of isatuximab to pomalidomide and dexamethasone extended OS compared to pomalidomide and dexamethasone in lenalidomide-refractory and proteasome inhibitor-refractory or relapsed MM.

Neither daratumumab nor bortezomib added to lenalidomide plus dexamethasone are cost-effective vs lenalidomide and dexamethasone alone for patients with newly diagnosed MM, according to a recent study.

Findings from a recent update on currently approved oncology biosimilars suggests that the use of biosimilars might provide competitive, lower-cost alternatives to biologics used in oncology.

Study findings revealed the web-based WRITE Symptoms interventions significantly improved symptom controllability for patients with ovarian cancer, regardless of delivery method.

Opportunistic salpingectomy at the time of elective cholecystectomy may be a cost-effective strategy to prevent ovarian cancer among average risk women.

Study findings confirm the long-term efficacy of autologous hematopoietic stem cell transplantation for treating MCL.

Study findings suggest that lower postdischarge health care utilization after robotic-assisted prostatectomy may offset the higher costs during the index hospitalization.

This systematic review of cost-effectiveness literature for novel diagnostic methods in prostate cancer shows that most studies have found novel methods to be more cost-effective than standard of care.

Study findings reveal primary prophylaxis with biosimilar filgrastim-sndz is cost-effective in patients with cancer at intermediate risk for febrile neutropenia.